Sanofi’s profits to dip as its dengue vaccine faces dire criticism
Date: 2017-11-30   Author: Dhananjay Punekar  Category: #news

Sanofi’s profits to dip as its dengue vaccine faces dire criticism

In a turning tide of the events, the use of Sanofi’s new vaccine for dengue has been severely restricted, owing to the evidence that it can lead to further deterioration in patients who have not been infected with the ailment before. The chief officials of Sanofi are expected to make suggestions to the national regulatory authorities in France that the vaccination should not be prescribed for patients who have no history of being infected by dengue.

As per medical experts, results obtained from the clinical tests performed on the patients a few years earlier depicted that the Dengvaxia vaccine offered a constant shield against dengue to those patients who were earlier affected due to the ailment. However, later on, it was found that people who were not afflicted by the virus suffered much more post the vaccination.

Initially, the firm had predicted bright growth prospects for its dengue vaccine, projecting that it would accrue a revenue of nearly EUR 1 billion per year from its sales. But, as per the estimates its sales in 2016 were assessed at EUR 55 million, much below expectations. A reliable research group has forecast that the yearly sales of Dengvaxia vaccine will reach EUR 360 million by 2022.  Sources have claimed that dengue infects millions across the globe and nearly 20,000 persons lose their lives due to the disease each year.

Though Sanofi’s Dengvaxia is the first approved vaccine of its kind, research has already depicted the limitations of vaccination through mixed results obtained from the data of clinical tests conducted on four dissimilar kinds of virus. It is anticipated that the business rivals of the firm such as Takeda Pharmaceutical are also developing an improved version of a vaccine against dengue, which can significantly impact Sanofi’s market position over the coming years.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Synthetic and Bio-based Thermoplastic elastomers (TPE) Market 2023 | Synthetic and Bio-based Thermoplastic elastomers (TPE) Market
Author: Rahul Varpe

Global synthetic thermoplastic elastomers (TPE) market size was estimated at over 4 million tons in 2015 and is likely to witness gains with an estimated CAGR of more than 4.5% up to 2023. Thermoplastic elastomers market revenue is likely to be va...


Emerson expands its portfolio of valves with A.E. Valves acquisition
Author: Sunil Hebbalkar

Emerson has taken over the Verviers headquartered Advanced Engineering (A.E.) Valves, a leading manufacturer of innovative valve technology. Through this acquisition, Emerson expects to serve its consumers with a wide ...


Industrial Thermostatic Control Valves Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast to 2023
Author: Partha Ray

Global Industrial Timer Market 2018 Includes Market Size, Share, Trends, Growth, Demand, Supply, Application, Segmentation, Opportunity, Market Development, Production, Capacity Utilization, Supply, Analysis and Forecast by 2023

Electronic t...